EMERALD TRIAL Open-Label Extension Study (EMERALD OLE)

Study Purpose:

EMERALD OLE trial is an open-label extension of the EMERALD trial. Long term tolerability and safety of the MediCabilis CBD oil has not been extensively studied. EMERALD OLE aims to establish data on the prolonged used of the study drug product.

All participants who completed the EMERALD trial will be offered to enter EMERALD OLE. Participants will be taking the active drug MediCabilis CBD oil for 6 months.

Study Status:

Not recruiting


Amyotrophic Lateral Sclerosis , Cannabis , CBD , Motor Neuron Disease

Study Type:


Type of Intervention:


Intervention Name:

MediCabilis CBD oil




Phase 4

Study Chair(s)/Principal Investigator(s):


Clinicaltrials.gov ID:


Neals Affiliated?


Coordinating Center Contact Information

Study Sponsor:

Gold Coast Hospital and Health Service

Estimated Enrollment:


Estimated Study Start Date:

05 / 17 / 2021

Estimated Study Completion Date:

01 / 01 / 2024

Posting Last Modified Date:

04 / 03 / 2023

Date Study Added to neals.org:

08 / 10 / 2021

Minimum Age:

25 Years

Maximum Age:

80 Years

Inclusion Criteria:

- Diagnosed with ALS/MND, either definite or probable according to the El Escorial revised criteria

- Can provide written informed consent

- Able and willing to comply with all study requirement

- Male or female, 25-80 years old

- Randomised into the EMERALD trial

Exclusion Criteria:

- Participants who are bedridden

- History of any psychiatric disorder other than depression associated with their underlying condition including immediate family history of schizophrenia

- Heavy consumption of alcohol or use of illicit drug

- Hypersensitivity to cannabinoids or any of the excipients

- Any of the following: eGFR <30 mL/min/1.73m2, ejection fraction <35%, or AST and ALT >5 X ULN

- Unwillingness of a female participant of child-bearing potential, or their partner, to use effective contraception during the study and 30 days thereafter

- Pregnant, lactating mother or female participant planning pregnancy during the course of the study and for 30 days thereafter

- Received any investigational drug or medical device within 30 days prior randomisation except MediCabilis CBD Oil

- Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study

- Inability to cooperate with the study procedures

- Unwilling to stop driving vehicle or operating dangerous machinery whilst on study drug.

- Close affiliation with the study team, e.g. close relative of the investigator

Gold Coast Hospital and Health Service

Gold Coast, Queensland 4215